Vasoactive Intestinal Peptide (VIP): Advanced Research Peptide
Vasoactive Intestinal Peptide (VIP) is a 28-residue neuropeptide with a highly conserved sequence: HSDAVFTDNYTRLRKQMAVKKYLNSILN. This peptide is extensively studied for its multifaceted biochemical roles in research settings, particularly its capacity to mediate complex signaling cascades in non-human test subjects.
VIP functions as a potent agonist for class B1 G protein-coupled receptors, specifically VPAC1 and VPAC2. Binding to these receptors initiates downstream activation of adenylate cyclase, resulting in elevated intracellular cyclic adenosine monophosphate (cAMP) levels. This cascade influences various physiological mechanisms, including smooth muscle relaxation, modulation of cytokine profiles, and enhancement of secretory pathways in experimental models.
In immunological studies, VIP demonstrates a capacity to regulate inflammatory mediators by suppressing pro-inflammatory cytokines such as TNF-α and IL-6 while upregulating anti-inflammatory counterparts like IL-10. These properties highlight its potential for exploring immune homeostasis. Moreover, VIP exhibits notable vasodilatory effects via nitric oxide-mediated pathways, making it a key focus in cardiovascular and circulatory studies involving test subjects.
The molecular formula of VIP, C147H238N44O42S, and its molecular weight of 3325.7 g/mol underscore its intricate structure and biochemical specificity. Its structural stability is often a subject of interest in synthetic peptide design, offering insights into peptide conformational dynamics under experimental conditions.
In laboratory research, VIP’s ability to interface between the neuroendocrine and immune systems makes it a versatile molecule for investigating systemic interconnectivity and cellular signaling intricacies. As a research peptide, it provides a robust tool for understanding the biochemical underpinnings of physiological regulation in laboratory test subjects.